An overview of mechanisms, biomarkers, and treatment strategies for acquired anti-EGFR resistance in RAS wild-type colorectal cancer
Colorectal cancer (CRC) is a threat to public health, with a global incidence and mortality of over 1.9 million and 0.9 million people, respectively. Anti-epidermal growth factor receptor (EGFR)-based treatment is recommended for CRC with wild-type rat sarcoma (RAS). However, after continuous treatm...
Sparad:
| Huvudupphov: | , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Frontiers Media S.A.
2025-09-01
|
| Serie: | Frontiers in Pharmacology |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1656372/full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|
